Novo Nordisk


Acknowledging the intensifying competition

06/06/25 -"While a more cautious approach to our estimates has resulted in c.11% reduction in the target price, we still see Novo as a good investment opportunity at the current share price levels. After a ..."

Pages
76
Language
English
Published on
06/06/25
You may also be interested by these reports :
12/06/25
Only a month ago we were lamenting the weakness of Pharmas, the second larget sector by market cap.  The tide may have turned, strangely as part ...

11/06/25
Faes Farma made a good move to acquire the Italian ophthalmology firm SIFI, whose enterprise value is c.20% of Faes’ market cap. This deal would not ...

11/06/25
A sector review of ytd performance would show that the money was on Aerospace Defence and Financials. Pain was to be experienced with Consumer ...

10/06/25
A pest threatens the 2025 potato harvest with failure rates of up to 70%. We believe the driest spring on record has contributed to this. In the ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO